Compare Abrdn Physical Platinum Shares ETF (PPLT) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abrdn Physical Platinum Shares ETF vs Repligen Corporation Common Stock — how do they compare? Abrdn Physical Platinum Shares ETF trades at $14.56 (market cap $2.00B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B). The key difference: Repligen Corporation Common Stock is far larger — about 5.6× Abrdn Physical Platinum Shares ETF's market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, Abrdn Physical Platinum Shares ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Abrdn Physical Platinum Shares ETF for 43 Days and Repligen Corporation Common Stock for 0 Days on average.
| PPLT | RGEN | |
|---|---|---|
Market Cap | $2.00B | $11.14B |
Volume | 1,178,871 | 1,259,263 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $25.23 | $194.57 |
52-Week Low | $13.73 | $102.87 |
Typical Hold Time | 43 Days | 0 Days |
Enterprise Value | — | $11.02B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PPLT, the abrdn Physical Platinum Shares ETF, trades at $15.05, down 1.44% with a bearish technical outlook. Moving averages signal strong selling pressure while oscillators remain neutral. Recent news highlights platinum's underperformance in the precious metals rally, with some analysts viewing it as a potential catch-up trade opportunity despite current bearish technicals.
The ETF faces headwinds from platinum's term structure in contango, suggesting adequate supply. Historical seasonality offers some counterpoint to the bearish outlook. Investment opportunity exists if platinum catches up to gold and silver's recent rally, though supply dynamics and technical weakness present near-term risks.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abrdn Physical Platinum Shares ETF
PPLT is a physically-backed ETF designed to track the spot price of platinum, less the Trust's expenses. It holds physical platinum bullion in secure vaults, providing investors with a liquid and cost-effective way to access the platinum market without the logistical challenges of direct ownership.
Read more on PPLT →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
